Methods for Identifying Out-of-Trend Results in Ongoing Stability Data - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Methods for Identifying Out-of-Trend Results in Ongoing Stability Data
The authors discuss three methods for identification of out-of-trend (OOT) results and further compare the z-score method and the tolerance interval in OOT analysis for stability studies.


Pharmaceutical Technology
Volume 37, Issue 6, pp. 46-51,59

Conclusion

The pharmaceutical industry still lacks having a proper guideline for the identification of present OOT results among ongoing stability data. As a result, many pharmaceutical companies are not harmonized in the way they conduct this type of analysis.

In this study, three methods for identification of OOT results in ongoing stability data were proposed: the regression-control-chart method, the by-time-point method, and the slope-control-chart method. To obtain more accurate identification of existing OOT results, simultaneous use of all three methods is advised, which will result in getting a visual image of the results of the analyzed batches. The use of the z-score method for defining the limits for the OOT results is preferred. Lastly, the study highlighted the necessity of issuing a regulatory confirmed guideline for identification of OOT results within ongoing stability data.

Adrijana Torbovska* is an analyst in the Quality Control Department of ReplekPharm, Kozle 188, 1000 Skopje, Macedonia,
Suzana Trajkovic-Jolevska, PhD, is a professor in the Drug Quality Control Department, Faculty of Pharmacy, Ss Cyril and Methodius University, Skopje, Macedonia.

* To whom all correspondence should be addressed.

References

1. MHRA, Guidance for Out Of Secification Investigation, online presentation, (2010), http://www.mhra.gov.uk/home/groups/comms-con/documents/websiteresources/con088215.pdf, accessed May 13, 2013.

2. FDA, Guidance for Industry: Investigating Out-Of-Specification (OOS) Test Results for Pharmaceutical Production (Rockville, MD, 2006).

3. PhRMA CMC Statistics and Stability Expert Teams, Pharm. Technol. 27 (4), 38-52 (2003).

4. ICH, Q1A (R2) Stability Testing of New Drug Substances and Products (Feb. 2003).

5. P.Rowe, Essential Statistics for the Pharmaceutical Sciences (John Wiley & Sons, West Sussex, UK, 2007), pp. 169-194.

6. W.W. Daniel, Biostatistics- A Foundation for Analysis in the Health Sciences (John Wiley & Sons, Hoboken, NJ, 9th ed., 2009), pp. 93-131, 215-304, and 409-484.

7. S. Bolton and C. Bon, Pharmaceutical Statistics–Practical and Clinical Applications (Marcel Dekker Inc., Monticello, NY, Vol. 135, 4th ed., 2004), pp. 96-150.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
8%
All of the above.
42%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology,
Click here